2-叔丁氧基羰基氨基-4-戊烯酸 | 119479-32-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-叔丁氧基羰基氨基-4-戊烯酸
• 中文别名: DL-N-BOC-烯丙基甘氨酸
• 英文名称: 2-((tert-butyloxycarbonyl)amino)-4-pentenoic acid
• 英文别名: N-Boc-allylglycine；2-tert-butoxycarbonylaminopent-4-enoic acid；Boc-allyl-Gly-OH；2-((tert-Butoxycarbonyl)amino)pent-4-enoic acid；2-[(2-methylpropan-2-yl)oxycarbonylamino]pent-4-enoic acid
• CAS: 119479-32-2
• 化学式: C₁₀H₁₇NO₄
• 分子量: 215.249
• InChiKey: BUPDPLXLAKNJMI-UHFFFAOYSA-N

物化性质

• 熔点：
  109 °C(Solv: dichloromethane (75-09-2); pentane (109-66-0))
• 沸点：
  352.0±35.0 °C(Predicted)
• 密度：
  1.097±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  储存条件：2-8℃，避光，干燥，密封。

反应信息

• 作为反应物：
  描述：

  2-叔丁氧基羰基氨基-4-戊烯酸 在 platinum on activated charcoal lithium hydroxide 、 lithium aluminium tetrahydride 、 Grubbs catalyst first generation 、 三氟甲磺酸二丁硼 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 氢气 、 双氧水 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醚 、 乙醇 、 二氯甲烷 为溶剂， 反应 98.75h， 生成
  参考文献：
  名称：

  Conformationally Constrained Analogues of Bleomycin A₅

  摘要：

  The bleomycin (BLM) group antitumor antibiotics are glycopeptide-derived natural products shown to cause sequence selective lesions in DNA. Prior studies have indicated that the linker region, composed of the methylvalerate and threonine residues, may be responsible for a conformational bend in the agent required for efficient DNA cleavage. We have synthesized a number of conformationally constrained methylvalerate analogues and incorporated them into deglycobleomycin A(5) congeners using our recently reported procedure for the solid phase construction of (deglyco)bleomycin and its analogues. These analogues were designed to probe the effects of conformational constraint of the native valerate moiety. Initial experiments indicated that the constrained molecules, none of which mimic the conformation proposed for the natural valerate linker, possessed DNA cleavage activity, albeit with potencies less than that of (deglyco)BLM and lacking sequence selectivity. Further experiments demonstrated that these analogues failed to produce alkali-labile lesions in DNA or sequence selective oxidative damage in RNA. However, two of the conformationally constrained deglycoBLM analogues were shown to mediate RNA cleavage in the absence of added Fe2+. The ability of the analogues to mediate the oxygenation of small molecules was also assayed, and it was shown that they were as competent in the transfer of oxygen to low molecular weight substrates as the parent compound.

  DOI：

  10.1021/ja030057w
• 作为产物：
  描述：

  ethyl 2-aminopent-4-enoate 在 sodium hydroxide 、 水 作用下， 以 二氯甲烷 为溶剂， 生成 2-叔丁氧基羰基氨基-4-戊烯酸
  参考文献：
  名称：

  Solution- and solid-phase synthesis of novel hydantoin and isoxazoline-containing heterocycles

  摘要：

  利用 1,3-二极环加成法和卡腈环化转化法，采用溶液法和固相法制备了新型异恶唑甲基咪唑烷二酮杂环。

  DOI：

  10.1039/a803400a

文献信息

• [EN] PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CALICO LIFE SCIENCES LLC

  公开号：WO2020186199A1

  公开（公告）日：2020-09-17

  Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN 1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

  本文提供了用于抑制蛋白酪氨酸磷酸酶的化合物、组合物和方法，例如蛋白酪氨酸磷酸酶非受体型2（PTPN2）和/或蛋白酪氨酸磷酸酶非受体型1（PTPN1），以及用于治疗对PTPN1或PTPN2抑制剂治疗有良好反应的相关疾病、紊乱和状况的方法，例如癌症或代谢性疾病。
• [EN] BENZIMIDAZOLE ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX À BASE DE BENZIMIDAZOLE
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011097491A1

  公开（公告）日：2011-08-11

  Provided are compounds of Formula (I) and (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

  提供的是公式(I)和(II)的化合物以及它们的药用可接受盐，它们的药物组合物，它们的制备方法，以及它们用于治疗由黄病毒科病毒家族成员如丙型肝炎病毒（HCV）介导的病毒感染。
• MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：McDaniel Keith F.

  公开号：US20120172291A1

  公开（公告）日：2012-07-05

  The present invention relates to novel fluorinated macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

  本发明涉及新型氟代大环化合物以及使用该大环化合物治疗需要此类治疗的乙型肝炎感染患者的方法。本发明还涉及包含本发明化合物的药物组合物，或其药学上可接受的盐、酯或前药，与药学上可接受的载体或赋形剂结合。
• Stereoselective ring contraction of 2,5-diketopiperazines: An innovative approach to the synthesis of promising bioactive 5-membered scaffolds
  作者：Thibault Coursindel、Audrey Restouin、Georges Dewynter、Jean Martinez、Yves Collette、Isabelle Parrot

  DOI：10.1016/j.bioorg.2010.05.002

  日期：2010.10

  Ring contraction of 2,5-diketopiperazines by TRAL-alkylation led us to the stereoselective synthesis of original pyrrolidine-2,4-diones, a novel series of promising molecules with moderate anti-proliferative activity on breast cancer cells.

  2，5-二酮哌嗪通过TRAL烷基环的收缩使我们得以立体选择性地合成了原始的吡咯烷2,4-二酮，这是一系列新的有前途的分子，对乳腺癌细胞具有中等的抗增殖活性。
• [EN] NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS<br/>[FR] NOUVEAUX MACROCYCLES EN TANT QU'INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013022818A1

  公开（公告）日：2013-02-14

  The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了化合物的公式(Ia)：或其立体异构体、互变异构体或药用可接受盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽原的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。